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Abstract
Background:  This study evaluated the cytotoxic and antiproliferative efficacy of two well-
characterized members of the Cecropin-family of antimicrobial peptides against bladder tumor cells
and benign fibroblasts.
Methods: The antiproliferative and cytotoxic potential of the Cecropins A and B was quantified
by colorimetric WST-1-, BrdU- and LDH-assays in four bladder cancer cell lines as well as in murine
and human fibroblast cell lines. IC50 values were assessed by logarithmic extrapolation, representing
the concentration at which cell viability was reduced by 50%. Scanning electron microscopy (SEM)
was performed to visualize the morphological changes induced by Cecropin A and B in bladder
tumor cells and fibroblasts.
Results:  Cecropin A and B inhibit bladder cancer cell proliferation and viability in a dose-
dependent fashion. The average IC50 values of Cecropin A and B against all bladder cancer cell lines
ranged between 73.29 μg/ml and 220.05 μg/ml. In contrast, benign fibroblasts were significantly less
or not at all susceptible to Cecropin A and B. Both Cecropins induced an increase in LDH release
from bladder tumor cells whereas benign fibroblasts were not affected. SEM demonstrated lethal
membrane disruption in bladder cancer cells as opposed to fibroblasts.
Conclusion: Cecropin A and B exert selective cytotoxic and antiproliferative efficacy in bladder
cancer cells while sparing targets of benign murine or human fibroblast origin. Both peptides may
offer novel therapeutic strategies for the treatment of bladder cancer with limited cytotoxic effects
on benign cells.
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Background
Depending on grade and stage, non-muscle invasive blad-
der cancers recur and progress in up to 80% of cases if
treated by transurethral resection (TUR) alone[1,2]. Post-
operative adjuvant intravesical instillations of chemother-
apeutic drugs such as mitomycin, doxorubicin or
epirubicin as well as immunotherapy with Bacillus Cal-
mette-Guérin (BCG) are established treatment options to
reduce tumor recurrences [3-5]. However, recurrence and
progression remain a serious threat to patients especially
with high risk non-muscle invasive bladder cancers even if
adjuvant intravesical treatment is performed according to
existing guidelines with BCG-immunotherapy plus main-
tenance. In this subgroup of patients, progression occurs
in more than 15% of cases [3,5-7]. Furthermore, intravesi-
cal chemotherapy and BCG-immunotherapy are both
associated with significant side effects. Toxicities vary
from mild cystitic symptoms to severe sepsis and have a
negative impact on patient compliance [8,9]. Therefore,
the identification of new potent intravesical agents is
highly desirable to reduce toxicity and to improve long-
term outcome.
Cecropin A and B belong to the Cecropin-family of anti-
microbial peptides which were first isolated from the
hemolymph of the giant silk moth Hyalophora cecropia
[10-12]. Antimicrobial peptides are important compo-
nents of the innate immune defense against microbial
pathogens in a wide range of organisms including
humans [13,14]. Cecropin A and B exert strong antibiotic
activity against both Gram-positive and -negative bacteria
in micromolar concentrations [10,15]. Cecropins have
the ability to form specific amphipathic alpha-helices
which allow them to target nonpolar lipid cell mem-
branes. Upon membrane targeting, they form ion-perme-
able channels subsequently resulting in cell
depolarization, irreversible cytolysis and finally death
[14,16]. Besides their well-known antimicrobial proper-
ties, recent studies have demonstrated specific tumori-
cidal activity of both Cecropin A and B against
mammalian leukemia, lymphoma and colon carcinoma
cell lines [17,18] as well as small cell lung cancer [19] and
gastric cancer cells [20]. In vivo, Cecropin B improves sur-
vival of mice bearing ascitic colon adenocarcinomas [18].
Transfection of human bladder cancer cells with Cecropin
genes reduces their tumorigenicity in nude mouse models
[21]. We have recently reported significant antitumor
activity of the structurally and functionally related antimi-
crobial peptide Magainin II against bladder cancer cell
lines in vitro [22]. Our aim in this study was to analyze the
antitumor efficacy of Cecropins against bladder cancer
cells and to evaluate their potential as a new therapeutic
option for intravesical treatment of non-muscle invasive
bladder cancer.
Methods
Peptides, cell lines and cell culture
Lyophilized Cecropin A and B were purchased from
Bachem AG (Heidelberg, Germany) and reconstituted in
serum-free RPMI 1640 (Sigma) or Dulbecco's modified
Eagle medium (DMEM, Gibco BRL), respectively. The
four established human bladder cancer cell lines RT4
(grade 1), 647V (grade 2), J82 (grade 3) and 486P (grade
4) were originally obtained from the American Type Cul-
ture Collection (ATCC; Rockville, MD). The mouse
fibroblast cell line 3T6 was purchased from the German
Collection of Microbiology and Cell Culture (DSMZ;
Braunschweig, Germany). Primary fibroblasts from
human gingival tissue samples were isolated using a
standard protocol and termed ZF07 [23]. Cells were cul-
tured under standard conditions as described previously
[22]. For cytotoxicity and proliferation assays, cells were
seeded in 96-well microtiter plates in a total volume of
200 μl. Cells were cultivated for 24 h before the respective
test substances were added after changing the culture
medium.
Cell viability assay
The WST-1 cell viability assay (Roche Molecular Biochem-
icals; Mannheim, Germany) is based on the cleavage of
the tetrazolium salt WST-1 to form a red formazan dye by
viable cells and was performed according to the manufac-
turer's instructions [22]. Cells in microtiter plates were
incubated for 24 h with various concentrations of Cecro-
pin A or B as indicated in figure legends. Absorbance of
the colored formazan was determined using an auto-
mated microplate reader at 450 nm/620 nm wavelength
(LambdaE, MWG Biotech, Ebersberg, Germany). The
mean absorbance of control wells (cells without Cecro-
pin) represented 100% cell viability. Viability of Cecro-
pin-treated cells was determined in triplicate and related
to the absorbance of control cells.
Cell proliferation assay
Cell proliferation was measured with the BrdU cell prolif-
eration enzyme-linked immunosorbent assay (ELISA) kit
(Roche Molecular Biochemicals; Mannheim, Germany)
according to the manufacturer's instructions using an
automated microplate reader [22]. Cells were incubated
for 24 h in various concentrations of Cecropin A or B in
microtiter plates at a final volume of 200 μl/well as indi-
cated in figure legends. As a control for the replication of
DNA synthesis, cells were cultured without addition of
Cecropins. The mean absorbance of control cells repre-
sented 100% cell proliferation, and mean absorbance of
treated cells was related to control values to determine
sensitivity. Cell proliferation (% of control) was deter-
mined in triplicate.BMC Urology 2008, 8:5 http://www.biomedcentral.com/1471-2490/8/5
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Cell cytotoxicity assay
To detect direct Cecropin-induced cell lysis we performed
LDH-release assays (Roche Molecular Diagnostics; Man-
nheim, Germany) according to the manufacturer's
instructions [22]. Target cells were seeded in microtiter
plates for 24 h and incubated with various concentrations
of Cecropins for another 24 h. To determine the maxi-
mum LDH-release, cells were treated with 2% triton-X100
(Sigma; Taufkirchen, Germany) for 10 minutes before
running the assay. Untreated cells served as controls for
spontaneous LDH-release. Specific LDH-release was cal-
culated according to the following formula: LDH-release
% = 100 × (Exp-Spo)/(Max-Spo), with Exp representing
experimental release, Spo representing baseline release
and Max representing Maximum LDH-release.
Scanning electron microscopy (SEM)
Clean coverslips were placed at the bottom of two12-well
plates. At least 3 × 104 cells/well were seeded and covered
by 1 ml serum-free medium. Plates were incubated over-
night and final concentrations of Ceropins were added for
30–90 min the next day as indicated in figure legends.
After removing supernatants, 1 ml 4% formalin solution
(Sigma; Taufkirchen, Germany) was added to each well.
Following fixation, all coverslips were impregnated in
2.5% tannic acid (Sigma; Taufkirchen, Germany) for 2
days. Counter-fixation in 2% osmium tetroxide (Sigma;
Taufkirchen, Germany) for 2 hours was followed by dehy-
dration in ethanol and drying in a critical point dryer (Ion
Tech Ltd.; Teddington, UK). Cells on coverslips were
coated with gold and analyzed using a XL 20 scanning
electron microscope (Philips; Kassel, Germany).
Statistical analysis
All experiments were performed at least in triplicate. The
Mann-Whitney U test (Bias 8.1 for Windows) was used to
calculate p values. A p < 0.05 was considered statistically
significant.
Results
Cecropins inhibit bladder tumor cell viability and 
proliferation
The impact of Cecropins A and B on bladder tumor cell
viability and proliferation was assessed by WST-1 and
BrdU assays. Cecropin A and B both inhibit the viability
of bladder cancer cells in a dose-dependent fashion. The
average IC50 values of Cecropin A and B against all bladder
cancer cell lines were 220.05 μg/ml (range 185.39 –
251.47 μg/ml) and 139.91 μg/ml (range 97.93 – 184.81
μg/ml), respectively. In contrast, target cells of benign
fibroblast origin such as ZF07 and 3T6 showed signifi-
cantly higher IC50 values in WST-1 assays as compared to
bladder tumor targets (p < 0.05). IC50 values of Cecropin
B against ZF07 and 3T6 cells averaged 573.03 μg/ml
(range 413.92 – 732.14 μg/ml) while the IC50 of Cecropin
A could only be determined against ZF07 cells with
649.03 μg/ml (Fig. 1A + B and Table 1).
Cecropin A and B both inhibit BrdU incorporation in all
bladder cancer cells tested in a dose-dependent fashion.
The average IC50 values of Cecropin A and B against all
bladder cancer cell lines were 73.29 μg/ml (range 28.74 –
99.01 μg/ml) and 79.94 μg/ml (range 61.86 – 92.9 μg/
ml), respectively. Again, in contrast to benign fibroblasts,
bladder tumor cells are significantly more susceptible to
Cecropin A and B-induced inhibition of proliferation (p <
0.05). IC50 values against ZF07 and 3T6 cells could nei-
ther be determined for Cecropin A nor B (Fig. 1C + D and
Table 1). In summary, Cecropin A and B both show a
selective inhibitory effect on bladder cancer cell viability
and proliferation as compared to target cells of benign ori-
gin such as fibroblasts.
Cecropins induce direct tumor cell lysis
Cecropin A and B both induce an increase in LDH-release
from bladder cancer cells in a dose-dependent fashion.
The direct lytic activity of the Cecropins was slightly less
pronounced as compared to their inhibitory effect on
tumor cell viability and proliferation. The average IC50 of
Cecropin A against 486P, RT4, 647V and J82 bladder can-
cer cell lines was 295.6 μg/ml (range 200.7 – 373.3 μg/
ml). The average IC50 of Cecropin B against 486P, RT4,
647V and J82 bladder cancer cell lines was 212.6 μg/ml
(range 181.1 – 240.4 μg/ml). Bladder tumor cells are sig-
nificantly more susceptible to Cecropin A and B-induced
cytolysis (p < 0.05) than benign fibroblasts. IC50 values
against ZF07 and 3T6 cells could neither be determined
for Cecropin A nor B (Fig. 1E + F and Table 1). In sum-
mary, Cecropin A and B both demonstrate selective cyto-
toxicity against bladder cancer cells as compared to target
cells of benign origin such as fibroblasts.
Cecropins induce target bladder tumor cell membrane 
disruption
Antimicrobial peptides of the Cecropin-family can target
nonpolar lipid cell membranes resulting in formation of
ion-permeable channels which leads to depolarization,
irreversible cytolysis and finally death of the target cells
[14,16]. We examined the morphological changes on the
cell membrane of 486P bladder tumor cells and ZF07
human gingival fibroblasts induced by Cecropin A and B
using scanning electron microscopy (SEM). While
untreated 486P cells show a smooth surface, treatment
with 65 μM of the most potent peptide Cecropin B
induces significant cell membrane disruption. In contrast,
untreated and Cecropin B-treated ZF07 cells display unaf-
fected cell morphology without membrane damage (Fig.
2). Cecropin A treatment of tumor cells induces similar,
however less pronounced, morphological changes (data
not shown).BMC Urology 2008, 8:5 http://www.biomedcentral.com/1471-2490/8/5
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Impact of Cecropin A and B on bladder cancer cells and fibroblasts Figure 1
Impact of Cecropin A and B on bladder cancer cells and fibroblasts. The four bladder cancer cell lines RT4, 647V, J82 and 486P 
as well as human (ZF07) and murine (3T6) fibroblasts were coincubated with increasing concentrations of up to 400 μg/ml 
Cecropin A and B. Cecropin A (A) and B (B) both demonstrate significant inhibitory activity on the viability of all four bladder 
cancer cell lines as measured by the WST-1 cell viability assay. In contrast, benign fibroblasts are less susceptible to Cecropin 
(p < 0,05). Additionally, Cecropin A (C) and B (D) both demonstrate significant inhibitory activity on the proliferation of all 
four bladder cancer cell lines as measured by the BrdU proliferation assay. In contrast, benign fibroblasts are not susceptible to 
Cecropin (p < 0,05). Cecropin A (E) and B (F) both exert significant cytotoxicity against all bladder cancer cell lines as meas-
ured by the LDH release assay. In contrast, benign fibroblasts are not susceptible to Cecropin-mediated cytolysis (p < 0,05). 
Experiments were performed in triplicate with results shown as mean ± standard deviation.
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Table 1: Effect of Cecropin A and B on cell viability, proliferation and cytotoxicity
Cell line Cell viability
WST-1 IC50 (μg/ml)
Cecropin A/B
Cell proliferation
BrdU IC50 (μg/ml)
Cecropin A/B
Cytotoxicity
LDH IC50 (μg/ml)
Cecropin A/B
ZF07 649.03/732.14 ∅/∅∅ /∅
3T6 ∅/413.92 ∅/∅∅ /∅
486P 251.47/161.76 69.2/87.47 373.3/232.4
RT4 231.26/184.81 96.22/92.9 289.3/240.4
647V 185.39/115.12 28.74/61.86 200.7/181.1
J82 212.07/97.93 99.01/77.51 319.2/196.3
IC50 values were assessed by logarithmic extrapolation; ∅ = not assessable or concentration >10,000 μg/mlBMC Urology 2008, 8:5 http://www.biomedcentral.com/1471-2490/8/5
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Discussion
The innate immune system plays a crucial role in the early
defense against malignant tumor growth, and progressing
cancers eventually escape immune surveillance [24].
Recently, cytolytic cationic polypeptides which are impor-
tant components of the innate immune defense against
microbial pathogens were demonstrated to overcome this
resistance via yet unknown mechanisms [17-20,22,25-
27]. The results of the present study demonstrate signifi-
cant inhibition of tumor cell proliferation and DNA syn-
thesis following treatment with such polypeptides,
Cecropin A and Cecropin B, in all bladder cancer cell lines
tested. Additionally, both Cecropin A and B exert direct
tumor cell lysis, probably by target cell membrane disrup-
tion. Interestingly, lytic and antiproliferative action of the
Cecropins were restricted to malignant transformed cells
whereas benign fibroblast cells were spared from cytotox-
icity. Our results support previous findings from studies
reporting an antitumor effect of Cecropins. Moore et al.
were the first authors who described potent anticancer
activity of Cecropin B against a panel of mammalian
tumor cells [18]. Various tumor entities such as leukemia,
lymphoma, colon carcinoma, small cell lung cancer and
gastric cancer have also been described to be sensitive to
Cecropin-mediated cell lysis in vitro [17-20]. The
Cecropins share their potential antitumoral action with
structural analogues from related families of antimicro-
bial peptides such as Magainins or Defensins [22,25]. In
Effect of Cecropin B on cell membranes of 486P bladder cancer cells and ZF07 fibroblasts as visualized by scanning electron  microscopy (SEM) Figure 2
Effect of Cecropin B on cell membranes of 486P bladder cancer cells and ZF07 fibroblasts as visualized by scanning electron 
microscopy (SEM). (A) Representative example of an untreated 486P bladder cancer cell showing a smooth surface. (B) 486P 
cells treated with 65 μM Cecropin B reveal a disrupted cell membrane with only small islands of intact surface left (arrow). In 
contrast, untreated (C) ZF07 fibroblasts and (D) fibroblasts after incubation with 65 μM Cecropin B do not display any 
changes in cell morphology with no observable damage to the cell membrane.
A B
C DBMC Urology 2008, 8:5 http://www.biomedcentral.com/1471-2490/8/5
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the study by Lehmann et al., MagaininII was demon-
strated to exert a selective antitumoral potential and even
displayed pronounced antiproliferative and cytotoxic
activity on high grade as compared to low grade tumor
cells [22]. In our experiments, we found a similar trend
towards increased susceptibility of high grade tumor cells
against cecropins. However, this trend was not statistically
significant. The cytolytic mechanism of antimicrobial
peptides remains highly controversial. In addition to dis-
rupting the surface membrane of tumor cells which
induces cytolysis/necrosis, a second mechanism of action
has been implicated for tumor cell destruction: subgroups
of antimicrobial peptides are able to enforce disruption of
mitochondrial membranes which subsequently leads to
activation of apoptosis pathways [25]. However, this find-
ing needs to be confirmed in further studies.
Cecropins and other antimicrobial peptides are especially
promising candidates for anticancer therapy in humans
because they demonstrate several unique features: 1)
Their selectivity for malignant cells and their potentially
pronounced lytic activity against high-grade tumor cells
allow for an optimal therapy in vivo with low therapeutic
concentrations and limited side effects. The molecular
basis for this selective antitumor activity of antimicrobial
peptides has not yet been completely understood. Some
authors have suggested that certain physicochemical
attributes of the respective target cell membranes such as
differences in lipoprotein content or fluidity may explain
this phenomenon [28]. Furthermore, serum composition
has been shown to have an important impact on the activ-
ity of lytic peptides, with high concentrations of albumin
and low-density lipoprotein being particularly inhibitory
[29] 2) The antitumoral effect of Cecropins has been
hypothesized to be unaffected by the multidrug resistance
(MDR) phenotype observed in many cancer types. In clin-
ical practice, the continual emergence of drug resistance
hinders the activity of most standard anticancer agents.
Cecropins as well as other antimicrobial peptides have
been demonstrated to have significant lytic activity
against MDR cancer cells [18,30] 3) Classic chemothera-
peutic agents such as mitomycin which are widely used
for intravesical instillation are highly unstable in urine
[31]. In contrast, Cecropins are largely resistent against
serum and urine proteolysis because of their specific bio-
chemical structures [14], rendering them ideal candidates
for intravesical tumor therapy.
Most studies investigating the antitumoral action of
Cecropins and other antimicrobial peptides have been
performed in vitro, but data confirming this promising
potential in vivo are rare. Presumably, this is due to the fact
that highly potent peptides such as Cecropins immedi-
ately exert their lytic activity locally at the respective appli-
cation sites, making them unsuitable for systemic therapy.
Consequently, application of Cecropins in vivo has been
restricted to either hollow organs or anatomically
restricted sites such as the abdominal cavity or skin
[18,21]. Recently, however, Papo et al. were able to dem-
onstrate that specifically designed related peptides are
capable of overcoming many of the limitations associated
with their systemic application such as serum proteolysis
[27] Additionally, the same group identified a peptide
with selective in vivo antitumoral activity suitable for sys-
temic application [26]. Still, the urinary bladder repre-
sents an ideal target organ where antimicrobial peptides
could be administered intravesically, and the Cecropins
could act locally on bladder cancer cells.
Conclusion
In summary, Cecropin A and B exert significant selective
cytotoxic and antiproliferative efficacy in bladder cancer
cells while sparing targets of benign murine or human
fibroblast origin. Their unique mechanism of action
appears to depend at least partially on the disruption of
target cell membranes resulting in irreversible cytolysis
and cell destruction. Both, Cecropin A and B are promis-
ing candidates for further preclinical evaluation as intra-
vesical treatment options in non-muscle invasive bladder
cancer.
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